World Vaping Alliance Launches Campaign to Save Lives

Oct.26.2022
World Vaping Alliance Launches Campaign to Save Lives
The World Vape Alliance begins a European tour to promote the message that e-cigarettes can save millions of lives.

The World Vaping Alliance (WVA) is back. After launching its first campaign in the summer of 2021, it is once again spreading the message across Europe that electronic cigarettes can save millions of lives. This time, it began outside the European Parliament in Strasbourg.


The movement began for the first time in the summer of 2021 when WVA launched a new graffiti mural outside the European Parliament with a clear message: supporting electronic cigarettes can save the lives of 19 million people in Europe.


During the press conference, e-cigarette enthusiasts from across Europe and European Parliament member Peter Liese were in attendance. WVA Director Michael Landl emphasized the potential of e-cigarette products, stating that "vaping has the potential to save the lives of 19 million people in Europe." The following day, the European Parliament's Committee on Environment, Public Health and Food Safety (ENVI) met to discuss proposals aimed at reducing the harm caused by smoking. If they endorse smokers using e-cigarettes as a tool to combat smoking, they have the opportunity to make history and save lives. The message conveyed to them was clear - choose science and save lives.


WVA proposed the "Electronic Cigarette Products Directive" with its recommendations.


Meanwhile, at the start of this election campaign, representatives from WVA met with several members of the European Parliament to introduce their "Electronic Cigarette Product Directive" and demonstrate how e-cigarettes can be utilized as a tool to fully realize their potential for public health. Additionally, an art installation called "Don't Let 19 Million People Die" will be spread across ten cities in six countries from October to November 2022.


In addition, this movement will coincide with the ongoing review of tobacco legislation and the Tobacco Products Directive (TPD) across Europe. The WVA has previously participated in a public call by the European Commission to provide evidence against flavor bans and excessive regulation. Through this movement, the organization aims to once again give voice to the European smoking community and encourage smokers to share their experiences in quitting smoking.


Michael Randall, head of WVA, emphasized that managing smoking can save lives. "By supporting e-cigarette users, we can combat smoking through reasonable regulation and save the lives of 19 million people. The EU's call for evidence has reached a record-breaking 24,000 people, indicating that consumers want to reduce tobacco harm, and e-cigarettes have proven to be the most successful option. The EU needs to end the ongoing discussion about smoking and e-cigarettes that is burdensome and easily obtainable. It is time for the EU to fully support reducing tobacco harm and making e-cigarette users its core.


Statement:


This article is compiled based on third-party information and is intended solely for industry exchange and learning.


This article does not represent the views of 2FIRSTS and they cannot confirm the authenticity or accuracy of the content. The translation of this article is intended solely for industry communication and research purposes.


Due to limitations in translation ability, the translated article may not fully reflect the same meaning as the original. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign statements or positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
Dragos Constantinescu has officially taken up his role as Chief Financial Officer and Executive Director at British American Tobacco (BAT). He previously spent 16 years at BAT across finance and general management roles in Europe before joining Asahi in 2019 and becoming CEO of Asahi Europe & International in 2025. His return comes as BAT continues to advance its “A Better Tomorrow” transformation.
BAT
Sep.01
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia's federal government introduced a new illicit tobacco enforcement bill on September 10 that would strengthen evidentiary presumptions, representative sampling, seizure and forfeiture procedures, proceeds-of-crime powers and obligations for customs and logistics operators. The proposal follows the Combatting Illicit Tobacco Act 2026, which took effect in August and increased penalties while expanding investigative and asset-recovery tools. Together, the reforms extend Australia's crackdown from tougher criminal sanctions into import, logistics and evidentiary enforcement.
Sep.14
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08